Detalhe da pesquisa
1.
PKD1-Associated Arachnoid Cysts in Autosomal Dominant Polycystic Kidney Disease.
J Stroke Cerebrovasc Dis
; 30(9): 105943, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34175641
2.
Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Am J Nephrol
; 51(11): 881-890, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-33227802
3.
Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma.
BMC Urol
; 20(1): 133, 2020 Aug 28.
Artigo
Inglês
| MEDLINE | ID: mdl-32859201
4.
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Kidney Int
; 96(1): 159-169, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30898339
5.
Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
Clin Exp Nephrol
; 23(1): 100-111, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30097754
6.
Optimal equation for estimation of glomerular filtration rate in autosomal dominant polycystic kidney disease: influence of tolvaptan.
Clin Exp Nephrol
; 22(5): 1213-1223, 2018 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-29789986
7.
A potentially crucial role of the PKD1 C-terminal tail in renal prognosis.
Clin Exp Nephrol
; 22(2): 395-404, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28983800
8.
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
J Am Soc Nephrol
; 28(5): 1592-1602, 2017 May.
Artigo
Inglês
| MEDLINE | ID: mdl-27920153
9.
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Am J Kidney Dis
; 69(2): 210-219, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27856088
10.
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease.
Nephrol Dial Transplant
; 32(6): 969-975, 2017 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27190355
11.
Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients.
Clin Exp Nephrol
; 21(3): 375-382, 2017 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-27339446
12.
Relationship between intracranial aneurysms and the severity of autosomal dominant polycystic kidney disease.
Acta Neurochir (Wien)
; 159(12): 2325-2330, 2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-28884237
13.
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.
Nephrol Dial Transplant
; 31(11): 1887-1894, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-26681730
14.
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
N Engl J Med
; 367(25): 2407-18, 2012 Dec 20.
Artigo
Inglês
| MEDLINE | ID: mdl-23121377
15.
Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.
Clin Exp Nephrol
; 19(4): 746-52, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-25351823
16.
The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial.
Clin Exp Nephrol
; 19(5): 867-77, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25663351
17.
Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?
Nephrol Dial Transplant
; 29(9): 1710-9, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-24739484
18.
Predictors of septic shock in obstructive acute pyelonephritis.
World J Urol
; 32(3): 803-11, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24037335
19.
Kidney volume and function in autosomal dominant polycystic kidney disease.
Clin Exp Nephrol
; 18(1): 157-65, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23864346
20.
Juxtaglomerular apparatus-mediated homeostatic mechanisms: therapeutic implication for chronic kidney disease.
Expert Opin Pharmacother
; : 1-14, 2024 May 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38773961